Clinical Trial Update: Pegasys Long-Term Anti-Fibrotic Effect Co-Infection Trial (PERFECT) [Phase 3]

View source ↗

Summary

Phase 3 PERFECT trial evaluating Pegasys for long-term anti-fibrotic effects in HIV/HCV coinfection has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection
• Hepatitis C

Drugs mentioned

• Pegasys (pegylated interferon alfa-2a)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: HIV/HCV Coinfection | Phase 3 | Status: TERMINATED